Latest News for Galectin Therapeutics Stock (NASDAQ:GALT)

Monday, November 13, 2023

Galectin Therapeutics: Q3 Earnings Insights
Benzinga Insights - Nov 13, 2023, 8:50AM
Galectin Therapeutics' $20.4M Of Cash And Cash Equivalents And $30M Remaining Available Under A $60M Line Of Credit Provided By Its Chairman Is Sufficient Cash To Fund Currently Planned Operations And R&D Activities Through At Least December 31, 2024
Benzinga Newsdesk - Nov 13, 2023, 8:23AM
Galectin Therapeutics Q3 EPS $(0.24) Misses $(0.16) Estimate;
Benzinga Newsdesk - Nov 13, 2023, 8:23AM

Tuesday, October 03, 2023

Galectin Therapeutics Reports The Outcome Of The Fourth Data And Safety Monitoring Board Meeting For NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study Of Belapectin In Patients With Portal Hypertension Caused By Non-Alcoholic SteatoHepatitis Live
Benzinga Newsdesk - Oct 3, 2023, 8:02AM

Tuesday, September 26, 2023

Galectin Therapeutics To Present Update On Its Belapectin Liver Cirrhosis Program At The 20th Edition Of Discovery On Target Meeting, In Boston, September 25-28, 2023
Benzinga Newsdesk - Sep 26, 2023, 8:07AM

Tuesday, August 15, 2023

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk - Aug 15, 2023, 7:17AM

Monday, August 14, 2023

Galectin Therapeutics Q2 EPS $(0.15) Beats $(0.21) Estimate
Happy Mohamed - Aug 14, 2023, 8:21AM

Friday, July 21, 2023

Galectin Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
Lisa Levin - Jul 21, 2023, 7:24AM

Wednesday, May 17, 2023

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk - May 17, 2023, 6:25AM

Monday, May 15, 2023

Galectin Therapeutics Q1 EPS $(0.19) Beats $(0.21) Estimate; The Company Had $17.8 Million Of Cash And Cash Equivalents, And Expects That It Will Require More Cash To Fund Operations After December 31, 2024
Benzinga Newsdesk - May 15, 2023, 8:18AM

Thursday, March 30, 2023

Galectin Therapeutics Reports FY22 EPS Loss Of (0.65), Down From $(0.52) Loss A Year Ago
Benzinga Newsdesk - Mar 30, 2023, 7:59AM

Thursday, March 16, 2023

Galectin Therapeutics Reported The Outcome Of Its Third Data And Safety Monitoring Board Meeting For NAVIGATE Phase 2B/3 Study Of Belapectin For Liver Cirrhosis Caused By NASH, Interim Data From The Phase 2B Portion Is Expected In Q4 Of 2024
Benzinga Newsdesk - Mar 16, 2023, 8:08AM

Friday, March 03, 2023

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Benzinga Newsdesk - Mar 3, 2023, 11:50AM

Thursday, March 02, 2023

Galectin Therapeutics Provides Final Randomization Status Of NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
Happy Mohamed - Mar 2, 2023, 8:27AM

Wednesday, February 22, 2023

$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying
Lisa Levin - Feb 22, 2023, 8:40AM

Tuesday, February 07, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Feb 7, 2023, 12:31PM

Tuesday, January 24, 2023

Galectin Therapeutics Contribution To Improve Histology Interpretation Of Cirrhotic Liver Biopsies With Machine Learning Published In Prominent Gastroenterology Journal
Benzinga Newsdesk - Jan 24, 2023, 8:12AM

Thursday, January 05, 2023

Galectin Therapeutics Announces The End Of Enrollment Of Navigate, Its Seamless, Adaptive Phase 2B/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-alcoholic Steatohepatitis
Benzinga Newsdesk - Jan 5, 2023, 7:58AM

Monday, November 14, 2022

Galectin Therapeutics Q3 EPS $(0.14), Same YoY
Benzinga Newsdesk - Nov 14, 2022, 7:58AM

Wednesday, October 12, 2022

Galectin Therapeutics Receives FDA Approval To Proceed With Combination Immunotherapy Trial In Head And Neck Cancer
Bill Haddad - Oct 12, 2022, 7:54AM

Thursday, October 06, 2022

Galectin Therapeutics Reports The Outcome Of The Second Data And Safety Monitoring Board Meeting For NAVIGATE Phase 2b/3 Study Of Belapectin; DSMB Concluded That Navigate Can Continue As Designed, Without Modifications
Bill Haddad - Oct 6, 2022, 7:57AM

Thursday, September 29, 2022

CORRECTION: Correct Ticker For Galecto Is 'GLTO'
Benzinga Newsdesk - Sep 29, 2022, 6:05AM

Monday, August 15, 2022

Galectin Therapeutics Q2 EPS $(0.16) Down From $(0.15) YoY
Benzinga Newsdesk - Aug 15, 2022, 8:01AM

Monday, August 01, 2022

Around $30 Million Bet On This Communication Services Stock? 4 Penny Stocks Insiders Are Buying
Lisa Levin - Aug 1, 2022, 8:55AM

Friday, July 29, 2022

This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Lisa Levin - Jul 29, 2022, 5:55AM

Wednesday, July 27, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jul 27, 2022, 6:06PM

Tuesday, June 21, 2022

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations At The EASL International Liver Congress 2022
Benzinga Newsdesk - Jun 21, 2022, 8:00AM

Thursday, June 02, 2022

62 Biggest Movers From Yesterday
Lisa Levin - Jun 2, 2022, 6:10AM

Tuesday, May 24, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - May 24, 2022, 12:13PM

Tuesday, May 17, 2022

HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Lowers Price Target to $11
Benzinga Newsdesk - May 17, 2022, 7:17AM

Monday, May 16, 2022

Recap: Galectin Therapeutics Q1 Earnings
Benzinga Insights - May 16, 2022, 8:29AM
Galectin Therapeutics Q1 EPS $(0.17) Down From $(0.11) YoY
Benzinga Newsdesk - May 16, 2022, 8:09AM

Wednesday, May 11, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 11, 2022, 12:28PM

Wednesday, May 04, 2022

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - May 4, 2022, 12:29PM

Thursday, April 28, 2022

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Apr 28, 2022, 3:31PM

Thursday, April 14, 2022

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Apr 14, 2022, 5:48PM
Galectin Therapeutics Reports Outcome Of The First Data And Safety Monitoring Board For NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
Benzinga Newsdesk - Apr 14, 2022, 7:54AM

Monday, April 04, 2022

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Apr 4, 2022, 12:05PM

Friday, April 01, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Apr 1, 2022, 1:00PM

Thursday, March 31, 2022

Galectin Therapeutics: Q4 Earnings Insights
Benzinga Insights - Mar 31, 2022, 9:41AM
Galectin Therapeutics FY21 EPS $(0.52) vs $(0.41) In FY20
Benzinga Newsdesk - Mar 31, 2022, 8:10AM

Tuesday, March 29, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 29, 2022, 11:43AM

Monday, December 13, 2021

Galectin Therapeutics Discusses Corporate Transformation, Progress Of NAVIGATE Trial And Outlines Strategy For Potential Phase 2 Cancer Immunotherapy Trial At Annual Meeting
Benzinga Newsdesk - Dec 13, 2021, 8:10AM

Friday, December 10, 2021

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 10, 2021, 9:51AM

Monday, November 15, 2021

Galectin Therapeutics Q3 EPS $(0.14) Down From $(0.10) YoY
Luke J Jacobi - Nov 15, 2021, 8:08AM

Wednesday, October 27, 2021

Galectin Pharmaceuticals To Present 6 Scientific Abstracts At The Liver Meeting 2021, Hosted By AASLD
Benzinga Newsdesk - Oct 27, 2021, 8:03AM

Monday, August 16, 2021

Galectin Therapeutics Q2 EPS $(0.15) Down From $(0.11) YoY
Benzinga Newsdesk - Aug 16, 2021, 9:06AM

Tuesday, August 03, 2021

61 Biggest Movers From Yesterday
Lisa Levin - Aug 3, 2021, 4:45AM

Monday, August 02, 2021

40 Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Aug 2, 2021, 12:01PM

Wednesday, July 14, 2021

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Jul 14, 2021, 8:08AM

Open1.930	Close1.900
Vol / Avg.90.954K / 56.346K	Mkt Cap124.934M
Day Range1.840 - 1.930	52 Wk Range1.030 - 2.470

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Galectin Therapeutics Stock (NASDAQ:GALT)

Monday, November 13, 2023

Tuesday, October 03, 2023

Tuesday, September 26, 2023

Tuesday, August 15, 2023

Monday, August 14, 2023

Friday, July 21, 2023

Wednesday, May 17, 2023

Monday, May 15, 2023

Thursday, March 30, 2023

Thursday, March 16, 2023

Friday, March 03, 2023

Thursday, March 02, 2023

Wednesday, February 22, 2023

Tuesday, February 07, 2023

Tuesday, January 24, 2023

Thursday, January 05, 2023

Monday, November 14, 2022

Wednesday, October 12, 2022

Thursday, October 06, 2022

Thursday, September 29, 2022

Monday, August 15, 2022

Monday, August 01, 2022

Friday, July 29, 2022

Wednesday, July 27, 2022

Tuesday, June 21, 2022

Thursday, June 02, 2022

Tuesday, May 24, 2022

Tuesday, May 17, 2022

Monday, May 16, 2022

Wednesday, May 11, 2022

Wednesday, May 04, 2022

Thursday, April 28, 2022

Thursday, April 14, 2022

Monday, April 04, 2022

Friday, April 01, 2022

Thursday, March 31, 2022

Tuesday, March 29, 2022

Monday, December 13, 2021

Friday, December 10, 2021

Monday, November 15, 2021

Wednesday, October 27, 2021

Monday, August 16, 2021

Tuesday, August 03, 2021

Monday, August 02, 2021

Wednesday, July 14, 2021